NL-OMON55832招募中2 期
Individualized dosing of fludarabine during innate allo SCT: A randomized phase II study (TARGET Study) - TARGET Study
niversitair Medisch Centrum Utrecht0 个研究点目标入组 98 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Adults (>= 18 years)
- •2. AML, MDS, ALL, CML, CLL, NHL, HL, or a myeloproliferative disease (MPD)
- •3. Indication for allo-SCT according to the policy of the local center
- •4. WHO performance status <= 2
- •5. Written informed consent
排除标准
- •1. Relapse of disease within 5 months after previous allo-SCT
- •2. Bilirubin and/or transaminases > 2.5 x normal value*
- •3. Creatinine clearance < 40 ml/min
- •4. Cardiac dysfunction as defined by:
- •- Unstable angina or unstable cardiac arrhythmias
- •- NYHA classification > II (Appendix B)
- •- Cardiac symptoms and/or history of cardiac disease AND a cardiac ejection
- •fraction <45%
- •5. Active, uncontrolled infection
研究者
相似试验
招募中
不适用
Individualized dosing of fludarabine during innate allo SCT: A randomized phase II studyHematological malignancies, Allogeneic stem cell transplantation, personalized dosing of fludarabineNL-OMON24753niversity Medical Center Utrecht (UMCU)98
进行中（未招募）
1 期
Individualized dosing of fludarabine during innate allo SCT: A randomized phase II study (TARGET Study)AML, MDS, ALL, CML, CLL, NHL, HL, or a myeloproliferative disease (MPD)MedDRA version: 21.0Level: LLTClassification code 10000835Term: Acute leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10008948Term: Chronic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: HLGTClassification code 10025321Term: Lymphomas non-Hodgkin's T-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: PTClassification code 10077465Term: Myeloproliferative neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000356-18-NLniversity Medical Center utrecht98
招募中
Unknown
Investigations into the influence of fludarabine exposure on the outcomeof patients after CAR-T cell therapyC90C83Multiple myeloma and malignant plasma cell neoplasmsNon-follicular lymphomaDRKS00033974niversitätsklinikum Hamburg Eppendorf200
招募中
Unknown
Investigation of fludarabine exposure in relation to individual renal function in patients with allogeneic hematopoietic stem cell transplantation and patients with CART cell therapyPatients with allogeneic stem cell transplantation or CART cell therapyDRKS00033126niversitätsklinikum Hamburg-Eppendorf50
进行中（未招募）
1 期
Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in BelgiumCTIS2023-503723-26-00niversitair Ziekenhuis Gent50